KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:可得 入排置信度 0.98

Phase 3 Trial of Dose-Escalated Radiation Therapy and Standard Androgen Deprivation Therapy Versus Dose-Escalated Radiation Therapy and Enhanced Androgen Deprivation Therapy With Orteronel for Men With High-Risk Prostate Cancer (NRG/RTOG 1115).

Daniel A Hamstra, James J Dignam, Deborah W Bruner, M Dror Michaelson, François Bachand, Viraj Master, Mylin A Torres, Philip J Saylor, Robert E Wallace, Neha Vapiwala, Jason A Efstathiou, Mack Roach, Seth A Rosenthal, Adam Raben, Scott C Morgan, Vivek S Kavadi, Daniel E Spratt, Jeff M Michalski, Wendy Seiferheld, Stephanie L Pugh, Benjamin Movsas, Howard Sandler

Int J Radiat Oncol Biol Phys 123(5) 1247-1258

PMID40712984
PMCIDPMC12833922
DOI10.1016/j.ijrobp.2025.07.1425
发表日期2025-07-25
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录已完成可用 Figure 视觉审查,未识别 KM 曲线。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图;Figure 2:非 KM 图;Figure 3::AI 判定为 other。
摘要

摘要

PURPOSE: NRG/RTOG 1115 was a phase 3 trial evaluating the addition of orteronel, a CYP17A1 inhibitor, to radiation therapy (RT) plus androgen deprivation therapy (ADT) in men with high-risk prostate cancer. METHODS AND MATERIALS: The study was designed to evaluate overall survival for 900 men with high-risk prostate cancer (Gleason 9-10, prostate specific antigen (PSA) > 20, or clinical stage T2 or higher with Gleason ≥ 8). Patients were randomized 1:1 to standard of care (SOC) therapy (RT plus 2 years of ADT) or SOC plus 2 years of orteronel. RT entailed image guided conventionally fractionated dose-escalated external beam RT to the prostate and pelvis to 45 Gy using intensity modulated RT with either intensity modulated RT (to 79.2 Gy) or brachytherapy boost. Health-related quality of life (HRQOL) was measured using the Expanded Prostate cancer Index Composite (EPIC), Patient-Reported Outcome Measurement Information System (PROMIS) fatigue, and EQ-5D. Accrual was halted early because of discontinuation of orteronel development and the trial redesigned to focus on a composite biochemical failure endpoint. RESULTS: There were a total of 231 eligible randomized patients. Only 29% in the orteronel arm received ≥80% of the planned dose. With median follow-up of 6.2 years, the cumulative incidence of grade 3+ adverse events was higher on orteronel than on the standard arm (P < .001; hazard ratio [HR], 2.32; 95% CI, 1.52-3.47) with 5-year estimates of 59.0% and 35.1%, respectively. No significant differences in overall survival (P = .28; HR, 0.71; 95% CI, 0.39-1.32) or biochemical failure (P = .56; HR, 0.84; 95% CI, 0.47-1.51) were observed. Use of orteronel had a transient negative impact on all prostate cancer-specific QOL domains of the EPIC, but did not increase the magnitude of decline once RT started and had minimal impact on other HRQOL measures. CONCLUSIONS: The addition of orteronel to RT and ADT did not result in significant improvement in any efficacy outcomes, although information was limited by poor drug tolerance and early termination of accrual, thus limiting statistical power.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1CONSORT Flow Diagram
非 KM Figure
Figure 2Kaplan-Meier plot of Overall Survival (2A), and cumulative incidence plots of Composite Biochemical Failure (2B), Distant Failure (2C).
非 KM Figure
Figure 3:Mean (and 95% CI) scores for EPIC Bowel Summary (2A), Urinary Summary (2B), Sexual Summary (2C), Hormonal Summary (2D), EQ-5D Index (2E), and PROMIS Fatigue (2F).
非 KM Figure